What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide”In the company’s words, NCT04684147 on ClinicalTrials.gov
- Tested for
- Relapsed or Refractory Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia
- Main trialPhase 2
- “The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.”In the company’s words, NCT04684147 on ClinicalTrials.gov
Other drugs for Relapsed or Refractory Acute Lymphoblastic Leukemia
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 22 Sep 2022 | Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia | |
| Phase 2Recruiting | 30 Mar 2024 | Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | |
| Phase 1/2Recruiting | 30 May 2025 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | |
| Phase 1Completed | 1 Dec 2020 | A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | |
| Phase 1Completed | 1 Jan 2021 | A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026